- Announced
initial data from the its Phase 1/2 ASPEN-02 study of evorpacept in
combination with azacitidine for the treatment of patients with
previously untreated higher-risk or relapsed or refractory
myelodysplastic syndrome. The combination was well tolerated; among
efficacy results, in six previously untreated HR MDS response-evaluable
patients, three patients achieved an objective response and two achieved
stable disease. Trades at record lows.
Ticker:
ALXO
IPOs expected to price
- Kubient (NASDAQ:KBNT) on August 10 and
- Netstreit (NTST) on August 12.
IPO lockup expirations
- Huize Holding (NASDAQ:HUIZ) on August 10,
- Revolution Medicine (NASDAQ:RVMD) and Trxade Group (NASDAQ:MEDS) on August 11.
IPO quiet period expirations
- nCino (NASDAQ:NCNO), GoHealth (NASDAQ:GOCO), Relay Therapeutics (NASDAQ:RLAY) and Trean Insurance (NASDAQ:TIG) on August 10,
- ALX Oncology (NASDAQ:ALXO), Pandion Therapeutics (NASDAQ:PAND), Berkeley Lights (NASDAQ:BLI) and Renalytix (NASDAQ:RNLX) on August 11.
